RU2016147122A - Применение серелаксина для снижения gdf-15 - Google Patents

Применение серелаксина для снижения gdf-15 Download PDF

Info

Publication number
RU2016147122A
RU2016147122A RU2016147122A RU2016147122A RU2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A
Authority
RU
Russia
Prior art keywords
serelaxin
patient
biological sample
administered
gdf
Prior art date
Application number
RU2016147122A
Other languages
English (en)
Russian (ru)
Other versions
RU2016147122A3 (cg-RX-API-DMAC10.html
Inventor
Маргарет Форни ПРЕСКОТТ
Имин ЧЖАН
Марион ДАЛЬКЕ
Томас СЕВЕРИН
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2016147122A publication Critical patent/RU2016147122A/ru
Publication of RU2016147122A3 publication Critical patent/RU2016147122A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
RU2016147122A 2014-06-13 2015-06-10 Применение серелаксина для снижения gdf-15 RU2016147122A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (2)

Publication Number Publication Date
RU2016147122A true RU2016147122A (ru) 2018-07-16
RU2016147122A3 RU2016147122A3 (cg-RX-API-DMAC10.html) 2019-01-28

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016147122A RU2016147122A (ru) 2014-06-13 2015-06-10 Применение серелаксина для снижения gdf-15

Country Status (11)

Country Link
US (2) US20170100460A1 (cg-RX-API-DMAC10.html)
EP (1) EP3154559B1 (cg-RX-API-DMAC10.html)
JP (1) JP6820748B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170018829A (cg-RX-API-DMAC10.html)
CN (1) CN106413740A (cg-RX-API-DMAC10.html)
AU (2) AU2015273097A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016028833A2 (cg-RX-API-DMAC10.html)
CA (1) CA2952061A1 (cg-RX-API-DMAC10.html)
MX (1) MX2016016414A (cg-RX-API-DMAC10.html)
RU (1) RU2016147122A (cg-RX-API-DMAC10.html)
WO (1) WO2015189790A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
EP3988031A4 (en) * 2019-06-20 2022-08-10 Sony Group Corporation Information processing device, information processing method, and program

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
US8415301B2 (en) * 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2017519008A (ja) 2017-07-13
BR112016028833A2 (pt) 2017-08-22
CN106413740A (zh) 2017-02-15
CA2952061A1 (en) 2015-12-17
KR20170018829A (ko) 2017-02-20
JP6820748B2 (ja) 2021-01-27
AU2018202289A1 (en) 2018-04-26
US20190022189A1 (en) 2019-01-24
RU2016147122A3 (cg-RX-API-DMAC10.html) 2019-01-28
EP3154559B1 (en) 2021-09-01
AU2015273097A1 (en) 2016-11-17
MX2016016414A (es) 2017-04-10
WO2015189790A1 (en) 2015-12-17
EP3154559A1 (en) 2017-04-19
US20170100460A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
McEwan et al. Autocrine regulation of wound healing by ATP release and P2Y2 receptor activation
Grodin et al. Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF
EA201892347A1 (ru) Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов
JP2017519008A5 (cg-RX-API-DMAC10.html)
JP2011510327A5 (cg-RX-API-DMAC10.html)
EA201390543A1 (ru) Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
Batal et al. Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving≤ 2 years and those surviving≥ 5 years after baseline right-sided cardiac catheterization
EP4552696A3 (en) Methods for predicting drug responsiveness in cancer patients
Takase et al. Evaluation of risk for incident hypertension using glomerular filtration rate in the normotensive general population
Turgut et al. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival
Ehrnthaller et al. Alteration of complement hemolytic activity in different trauma and sepsis models
Bilen et al. High-grade inflammation in renal failure patients, according to mean platelet volume, improves at the end of two years after transplantation
Bonella et al. C42 SEARCHIN'FOR A CURE: NEW ILD TREATMENTS: Serum Kl-6 Levels Correlate With Response To Pirfenidone In Idiopathic Pulmonary Fibrosis
Ruiz-Rodríguez et al. Characterization and Outcomes of Septic Shock Patients with Macrophage Activation-Like Syndrome: Prognostic Role of Hyperferritinemia and Description of Hemoadsorption in Refractory Hyperinflammatory Septic Shock
Perfetti et al. Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome
Mayor New blood marker can detect chronic kidney disease, study shows
Leclerc et al. Persistence of antibodies to infliximab for more than two months predicts loss of response to infliximab in inflammatory bowel diseases
RU2015130730A (ru) Способ прогнозирования чувствительности к химиотерапии у больных с лимфопролиферативными заболеваниями
Mikacenic et al. B24 MECHANISMS OF INJURY IN SEPSIS: INFLAMMATION, OXIDATION, AND ENDOTHELIAL DAMAGE: Biomarkers Of Endothelial Activation And Apoptosis Are Associated With Poor Outcomes In Critical Illness
Yadav et al. B47 ACUTE RESPIRATORY DISTRESS SYNDROME: Postoperative Acute Respiratory Distress Syndrome Is Associated With A Distinct Biomarker Profile: A Case Control Study
Ditsawanon et al. Inflammatory Biomarker pairs as outcome measures in peritoneal dialysis: a pilot study
Kendrick et al. S78 Lymphopaenia and increased ace levels stratify sarcoidosis patients to underlying increase in IFN-γ+ lymphocyte and TNF-α+ monocytes respectively
Vaes et al. Longitudinal changes in regular physical activity (PA) in subjects with and without COPD: Findings from the Copenhagen City heart study
Do Amaral et al. D38 UPDATE IN ALPHA ONE DEFICIENCY: Replacement Of Alpha-1-Antitrypsin (aat) Biweekly In Brazilian Patients With Chronic Obstructive Pulmonary Disease (COPD)
Uzaslan et al. D44 COPD: TREATMENT FROM BRONCHODILATORS TO OTHER PHARMACOLOGICAL INTERVENTIONS: How Ageing Effects Hospitalization In Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease?

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190610